Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 20, 2025Multiple Sclerosis Journal

Finite-course ocrelizumab in relapsing multiple sclerosis: Results of two prospective open-label trials with matched controls

View Full Paper
Ask AI
Bookmark
Share

Authors

ASAndrea Salazar-CameloLVLauren VegaYFYasser Fadlallah

Discussion

Loading...

Member takes

Overview

Prospective trials demonstrate ocrelizumab maintains remission in relapsing MS, highlighting a potential de-escalation strategy.

Key Points

  • Patients on finite ocrelizumab courses showed lower disease reactivation compared to matched controls.
  • In 19 participants receiving finite courses, disease reactivation occurred in 32%, unlike 0% in the SID group.
  • The analysis highlighted a 5.5-month earlier reactivation with finite courses compared to standard dosing.
  • These findings suggest significant potential for finite-course therapy as a viable de-escalation approach in MS.

Cite This Study

Salazar-Camelo et al. (2025) studied this question.

synapsesocial.com/papers/68d469ce31b076d99fa66bfchttps://doi.org/10.1177/13524585251375350
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Ocrelizumab exposure in relapsing–remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension2023 · 31 citations
  2. 2Proinflammatory GM-CSF–producing B cells in multiple sclerosis and B cell depletion therapy2015 · 463 citations
  3. 3A five-year observational prospective mono-center study of the efficacy of alemtuzumab in a real-world cohort of patients with multiple sclerosis2023 · 18 citations
  4. 4Alemtuzumab CARE-MS II 5-year follow-up2017 · 273 citations
  5. 5The recurrence of disease activity after ocrelizumab discontinuation in multiple sclerosis2024 · 6 citations